Clinical Activity Evaluation Of Enoxeparine Sodic In Health Vonlunteers And The Use Of Anti-xa Factor As A Mark Of Its Clinical Activity [estudo De Eficácia Clínica Da Enoxaparina Sodica Realizado Em Voluntários Sadios Utilizando A Dosagem Sanguínea Do Fator Anti-xa Como Marcador De Atividade]

[No abstract available]6635861Lindahl, U., Hook, M., Backstrom, G., Stricture and biosynthesis of heparin-like polysacsha-rides (1997) Federation Proceedings, 36, pp. 19-24Barrowcliffe, T.W., Curtis, A.D., Johnson, E.A., Thomas, A.P., An international standard for low molecular weight heparin (1988) Thrombosis and Haemostasis, 60, p. 1Hirsh, J., Levine, M.N., Low molecular weight heparin (1992) Blood, 79, pp. 1-17Bjork, I., Lindahl, U., Mechanism of the anticoagulant action of heparin (1982) Molecular and Cellular Biochemistry, 48, p. 161Ellis, V., Scully, M.R., Kakkar, V.V., The relative molecular mass dependence of the antifactor Xa properties of heparin (1986) Biochemical Journal, 238, p. 329Preissner, K.T., Muller-Berghaus, G., Neutrlization and binding of heparin by S-protein/vitronectin in the inhibition of factor Xa by antitrombin III (1987) Journal of Biological Chemistry, 262, p. 12247Lojewski, B., Bacher, P., Iqbal 0, Evaluation of hemostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period (1995) Seminars in Thrombosis and Hemostasis, 21, pp. 228-239Lojewski, B., Bacher, P., Iqbal 0, Evaluation of hematologic alterations associated with daily administration of low-molecular-weight heparin (Mono-Embolex) for a 12-week period (1993) Seminars in Thrombosis and Hemostasis, 19 (SUPPL. 1), pp. 36-43Ocleford, P.A., Carter, C.J., Mitchell, L., Hirsh, J., Diosrdance between the anti-Xa activity and antithrombotic activity of an ultra-low molecular weight heparin fraction (1982) Thrombosis Research, 28, p. 401Henry, C.P., ten Cate, H., ten Cate, J.W., A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs (1985) Journal of Laboratory and Clinical Mledicine, 106, p. 187Bjornsson, T.0., Wolfram, B.S., Kitchell, B.B., Heparin Kinetics determined by three assay methods (1982) Clinical Pharmacology and Therapeutic, 31, p. 104Bara, L., Billaud, E., Gramond, G., Kher, A., Samama, M., Comparative kinetic of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration (1985) Thrombosis Research, 39, p. 631Bendetowicz, A.V., Beguin, S., Caplain, H., Hemker, H.C., Pharmacokinetic and pharmacodynamic of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison unfractionated heparin - a three way cross over study in human volunteers (1994) Thrombosis and Haemostasis, 71, pp. 305-313Bratt, G., Tornebohm, E., Lockner, D., Bergstron, K.L., A human pharmacological study comparing conventional heparin an d a low molecular weight heparin fragment (1985) Thrombosis and Haemostasis, 62, pp. 648-650Choay, J., Petitou, M., The chemistry of heparin: A way to understand its mode of action (1986) Medical Journal of Australia, 144, p.